XOMA – A BIOTECH ROYALTY AGGREGATORABOUT USROYALTY PORTFOLIOOPPORTUNITIESNEWSINVESTORSCONTACT XOMA plays a unique role in helping biotech companies achieve their goal of improving human health. We do this by acquiring the economic rights to future milestone and royalty payments associated with partnered pre-commercial clinical candidates. In return the seller receives non-dilutive, non-recourse funding to advance their internal

drug

ISCALIMAB UPDATE

As part of its R&D Day on December 5, 2019, Novartis highlighted the progress that has been made on iscalimab (CFZ533), a product candidate, for which XOMA (NASDAQ: XOMA) has the potential to earn royalties that are tiered from a mid-single to a low teens percentage rate based on sales levels, if this investigational compound is approved and commercialized. PHAGE DISPLAY PLATFORM The XOMA antibody platform is built as a combination of novel technologies and unique know-how. XOMA’s access to major commercial phage libraries provided us with special insight and knowledge to create top-performing custom libraries. Our novel expression-enhancing advancements improve the functional activity of our phage libraries.

In

INVESTOR RELATIONS :: XOMA CORPORATION (XOMA) XOMA plays a unique role in helping biotech companies achieve their goal of improving human health. We do this by acquiring the economic rights to future milestone and royalty payments associated with partnered pre-commercial clinical candidates. In return the seller receives non-dilutive, non-recourse funding to advance their internal

drug

XOMA ANNOUNCES OFFERING OF SERIES A CUMULATIVE PERPETUAL EMERYVILLE, Calif., Dec. 10, 2020 (GLOBE NEWSWIRE) -- XOMA Corporation (Nasdaq: XOMA) (“XOMA” or the “Company”) today announced it has commenced an underwritten registered public offering of shares of its Series A Cumulative Perpetual Preferred Stock, with liquidation preference of $25.00 per share (the “Preferred Stock”).

NTM-1632 – XOMA

All references to “portfolio” on this website refer strictly to milestone and/or royalty rights associated with a basket of drug products in development. NEWS & EVENTS :: XOMA CORPORATION (XOMA) XOMA has built a significant portfolio of products that are licensed to and being developed by other biotechnology and pharmaceutical companies. The Company’s portfolio of partner-funded programs spans multiple stages of the drug XOMA ANNOUNCES CLOSING OF RIGHTS OFFERING :: XOMA Raises $22 million from existing stockholders. EMERYVILLE, Calif., Dec. 20, 2019 (GLOBE NEWSWIRE) -- XOMA Corporation (Nasdaq: XOMA) (“XOMA” or the “Company”) today announced the closing of its previously announced rights offering (the “Rights Offering”). At the closing, XOMA sold and issued an aggregate of 626,805 shares of

its

ISCALIMAB (CFZ533) UPDATE :: XOMA CORPORATION (XOMA) Additionally, the relevant slides can be found on our website at www.xoma.com. Iscalimab, which originated from XOMA’s research collaboration with Chiron (acquired by Novartis), is a fully human monoclonal antibody blocking the CD40 – CD154 signaling pathway. Please note: Iscalimab (CFZ533) is an investigational compound.

TAK-169 – XOMA

TAK-169. A Study of TAK-169 in Participants With Relapsed or Refractory Multiple Myeloma. XOMA – A BIOTECH ROYALTY AGGREGATORABOUT USROYALTY PORTFOLIOOPPORTUNITIESNEWSINVESTORSCONTACT XOMA plays a unique role in helping biotech companies achieve their goal of improving human health. We do this by acquiring the economic rights to future milestone and royalty payments associated with partnered pre-commercial clinical candidates. In return the seller receives non-dilutive, non-recourse funding to advance their internal

drug

ISCALIMAB UPDATE

As part of its R&D Day on December 5, 2019, Novartis highlighted the progress that has been made on iscalimab (CFZ533), a product candidate, for which XOMA (NASDAQ: XOMA) has the potential to earn royalties that are tiered from a mid-single to a low teens percentage rate based on sales levels, if this investigational compound is approved and commercialized. PHAGE DISPLAY PLATFORM The XOMA antibody platform is built as a combination of novel technologies and unique know-how. XOMA’s access to major commercial phage libraries provided us with special insight and knowledge to create top-performing custom libraries. Our novel expression-enhancing advancements improve the functional activity of our phage libraries.

In

INVESTOR RELATIONS :: XOMA CORPORATION (XOMA) XOMA plays a unique role in helping biotech companies achieve their goal of improving human health. We do this by acquiring the economic rights to future milestone and royalty payments associated with partnered pre-commercial clinical candidates. In return the seller receives non-dilutive, non-recourse funding to advance their internal

drug

XOMA ANNOUNCES OFFERING OF SERIES A CUMULATIVE PERPETUAL EMERYVILLE, Calif., Dec. 10, 2020 (GLOBE NEWSWIRE) -- XOMA Corporation (Nasdaq: XOMA) (“XOMA” or the “Company”) today announced it has commenced an underwritten registered public offering of shares of its Series A Cumulative Perpetual Preferred Stock, with liquidation preference of $25.00 per share (the “Preferred Stock”).

NTM-1632 – XOMA

All references to “portfolio” on this website refer strictly to milestone and/or royalty rights associated with a basket of drug products in development. NEWS & EVENTS :: XOMA CORPORATION (XOMA) XOMA has built a significant portfolio of products that are licensed to and being developed by other biotechnology and pharmaceutical companies. The Company’s portfolio of partner-funded programs spans multiple stages of the drug XOMA ANNOUNCES CLOSING OF RIGHTS OFFERING :: XOMA Raises $22 million from existing stockholders. EMERYVILLE, Calif., Dec. 20, 2019 (GLOBE NEWSWIRE) -- XOMA Corporation (Nasdaq: XOMA) (“XOMA” or the “Company”) today announced the closing of its previously announced rights offering (the “Rights Offering”). At the closing, XOMA sold and issued an aggregate of 626,805 shares of

its

ISCALIMAB (CFZ533) UPDATE :: XOMA CORPORATION (XOMA) Additionally, the relevant slides can be found on our website at www.xoma.com. Iscalimab, which originated from XOMA’s research collaboration with Chiron (acquired by Novartis), is a fully human monoclonal antibody blocking the CD40 – CD154 signaling pathway. Please note: Iscalimab (CFZ533) is an investigational compound.

TAK-169 – XOMA

TAK-169. A Study of TAK-169 in Participants With Relapsed or Refractory Multiple Myeloma.

NEWS – XOMA

XOMA: The royalty aggregator that thinks like a biotech. By Guy Martin For biotech companies, the prospect of receiving non-dilutive, non-recourse funding to advance their assets even through the early stages of clinical development. Read More ».

ABOUT US – XOMA

XOMA plays a unique role in helping biotech companies achieve their goal of improving human health. We do this by acquiring the economic rights to future potential milestone and royalty payments associated with partnered pre-commercial clinical candidates. In return the seller receives non-dilutive, non-recourse funding to advance their

ROYALTY PORTFOLIO

Royalty Portfolio. XOMA has an expansive portfolio of assets that provides us the right to future potential royalty and milestone payments. These drug candidate assets are being developed by others. While some information on these therapeutic candidates is restricted by confidentiality agreements, in the table below you will find links

that

XOMA ANNOUNCES OFFERING OF SERIES A CUMULATIVE PERPETUAL EMERYVILLE, Calif., Dec. 10, 2020 (GLOBE NEWSWIRE) -- XOMA Corporation (Nasdaq: XOMA) (“XOMA” or the “Company”) today announced it has commenced an underwritten registered public offering of shares of its Series A Cumulative Perpetual Preferred Stock, with liquidation preference of $25.00 per share (the “Preferred Stock”). NEWS & EVENTS :: XOMA CORPORATION (XOMA) XOMA has built a significant portfolio of products that are licensed to and being developed by other biotechnology and pharmaceutical companies. The Company’s portfolio of partner-funded programs spans multiple stages of the drug ASSETS AVAILABLE FOR LICENSING Assets Available for Licensing. XOMA was a traditional biotech company for over 35 years. In 2017, we transformed our business operations, exiting the traditional biotech activities of discovery, research and development. Due to our legacy, we have one of the largest phage display libraries in the industry and several early stage monoclonal ISCALIMAB (CFZ533) UPDATE :: XOMA CORPORATION (XOMA) Additionally, the relevant slides can be found on our website at www.xoma.com. Iscalimab, which originated from XOMA’s research collaboration with Chiron (acquired by Novartis), is a fully human monoclonal antibody blocking the CD40 – CD154 signaling pathway. Please note: Iscalimab (CFZ533) is an investigational compound. JNJ-63723283 (CETRELIMAB) JNJ-63723283 (cetrelimab) A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of JNJ-63723283, an Anti-Programmed Cell Death (PD)-1 Monoclonal Antibody, as Monotherapy or in Combination With Erdafitinib in Japanese Participants With Advanced Solid Cancers. A Study of JNJ-63723283, an Anti-programmed Death-1 MANAGEMENT TEAM :: XOMA CORPORATION (XOMA) Mr. Burns has 20 years of experience in accounting and finance in both biotechnology and high technology companies. Prior to XOMA, he held multiple senior financial management positions at high-tech companies including Mattson Technology, IntruVert Networks (acquired by McAfee), Niku Corporation (acquired by Computer Associates) and Conner XOMA_CURRENT_FOLIO_10K ☒ annual report pursuant to section 13 or 15(d) of the securities exchange act of 1934 . for the fiscal year ended december 31, 2019 . or ☐ transition report pursuant to section 13 or 15(d) of the securities exchange act of 1934 for the transition period from to

Skip to content

Menu

* About Us

* Overview

* Management Team

* Board of Directors

* Contact Us

* Royalty Portfolio

* Opportunities

* Overview

* Royalty Acquisition * Assets Available for Licensing * Phage Display Platform

* IL-2 Antibody

* Anti-prolactin Antibody

* XMetA Portfolio

* Anti-PTH1R Antibody

* News

* Company & Partner News

* Press Releases

* Investors

* Overview

* News & Events

* Financial Information

* Stock Data

* Analyst Coverage

* SEC Filings

* Governance

* Contact

Menu

* About Us

* Overview

* Management Team

* Board of Directors

* Contact Us

* Royalty Portfolio

* Opportunities

* Overview

* Royalty Acquisition * Assets Available for Licensing * Phage Display Platform

* IL-2 Antibody

* Anti-prolactin Antibody

* XMetA Portfolio

* Anti-PTH1R Antibody

* News

* Company & Partner News

* Press Releases

* Investors

* Overview

* News & Events

* Financial Information

* Stock Data

* Analyst Coverage

* SEC Filings

* Governance

* Contact

Menu

* About Us

* Overview

* Management Team

* Board of Directors

* Contact Us

* Royalty Portfolio

* Opportunities

* Overview

* Royalty Acquisition * Assets Available for Licensing * Phage Display Platform

* IL-2 Antibody

* Anti-prolactin Antibody

* XMetA Portfolio

* Anti-PTH1R Antibody

* News

* Company & Partner News

* Press Releases

* Investors

* Overview

* News & Events

* Financial Information

* Stock Data

* Analyst Coverage

* SEC Filings

* Governance

* Contact

WE ARE A BIOTECH ROYALTY AGGREGATOR WITH 65+ ASSETS AND GROWING. XOMA plays a unique role in helping biotech companies achieve their goal of improving human health. We do this by acquiring the economic rights to future milestone and royalty payments associated with partnered pre-commercial clinical candidates. In return the seller receives non-dilutive, non-recourse funding to advance their internal

drug candidate(s).

LEARN MORE

ROYALTY PORTFOLIO

We have an expansive portfolio of licenses that provides us the right to future potential royalty and milestone payments.  The drug candidate assets underlying the licenses are being developed by

others.

__ learn more

ROYALTY ACQUISITION

We are actively acquiring the rights to future potential milestone and royalty payments to pre-commercial therapeutic assets being developed by pharmaceutical and biotech companies.

__ learn more

INVESTOR RELATIONS

We use a portfolio approach to acquire new royalty assets, thereby mitigating single-asset binary exposure, and we operate under a capital-efficient structure to strive to deliver shareholder value.

__ learn more

REGISTER FOR NEWS UPDATES: Subscribe to our company news email list and receive XOMA news as it is released. To protect your privacy, your email address will be used only for this news distribution list. Leave this field empty if you’re human:

April 2020

DOWNLOAD OUR LATEST PRESENTATION:

DOWNLOAD NOW »

ISCALIMAB UPDATE

DECEMBER 5, 2019

See the latest Iscalimab update from the Novartis December R&D Day

__ View PDF

LATEST NEWS

* XOMA Reports Fourth Quarter and Full-Year 2019 Financial Results and Operating Highlights

March 10, 2020

* Zydus and XOMA Announce IL-2-Based Immuno-Oncology Therapy

Licensing Agreement

March 9, 2020

* XOMA to Present at the Cowen and Company 40th Annual Health Care

Conference

February 25, 2020

* Terms of Use

� 2019 XOMA Corporation.  All rights reserved. Any references to “portfolio” on this website refer strictly to milestone and/or royalty rights associated with a basket of drug products in development.  Any references to “assets” on this website refer strictly to milestone and/or royalty rights associated with individual drug products in development.

* Follow us:

*

*

� 2020 XOMA • Powered by GeneratePress

Scroll back to top